实用医学杂志 ›› 2024, Vol. 40 ›› Issue (16): 2224-2228.doi: 10.3969/j.issn.1006-5725.2024.16.005

• 专题笔谈 • 上一篇    下一篇

糖尿病足血清学诊断标志物的研究进展

杨卡明1,李贞林1,劳琬文1,翟爱霞2,毕长龙1()   

  1. 1.中山大学附属第八医院,内分泌科,(广东 深圳 518033 )
    2.中山大学附属第八医院,检验科,(广东 深圳 518033 )
  • 收稿日期:2024-02-21 出版日期:2024-08-25 发布日期:2024-08-26
  • 通讯作者: 毕长龙 E-mail:BCL163@163.com
  • 作者简介:毕长龙,博士,博士后合作导师,硕士研究生导师,中山大学附属第八医院糖尿病足诊疗中心主任,伤口创面治疗中心副主任,主任医师,中华医学会内分泌学分会十一届分会神经与内分泌学组委员,中国医药教育协会临床抗感染药物评价与管理分会委员,中华预防医学会组织感染与损伤预防与控制专业委员会委员,中国研究型医院学会创面防治与损伤组织修复专业委员会委员,中国微循环学会糖尿病与微循环专业委员会青年委员,广东省健康管理学会创面修复专业委员会委员,广东省医院协会糖尿病管理专业委员会委员,深圳市医师协会骨质疏松症和骨矿盐疾病工作委员会常务委员。
  • 基金资助:
    国家自然科学基金项目(82172215);广东省基础与应用基础研究基金项目(2021A1515012109);深圳市科技创新委员基础研究专项面上项目(JCYJ202308 07111302006);深圳市福田区卫生健康系统科研项目(FTWS2023056)

Serological biomarkers for diagnosis of diabetes foot: A review of literature

Kaming YANG1,Zhenlin LI1,Wanwen LAO1,Aixia ZHAI2,Changlong. BI1()   

  1. *.Department of Endocrinology,the Eighth Affiliated Hospital,Sun Yat?sen University,Shenzhen 518033,China
  • Received:2024-02-21 Online:2024-08-25 Published:2024-08-26
  • Contact: Changlong. BI E-mail:BCL163@163.com

摘要:

糖尿病足(diabetic foot, DF)是糖尿病的一种主要慢性并发症,也是糖尿病患者致残和致死的主要原因。目前,DF的诊断主要依赖临床表现、体征及相关辅助检查,生物学标志物的发现及应用对DF的临床诊疗提供重要帮助。随着生物学的发展,除广泛应用的降钙素原(procalcitonin, PCT)、C反应蛋白(C-reactive protein, CRP)、白细胞介素(interleukins, ILs)和肿瘤坏死因子-α(tumor necrosis factor-alpha, TNF-α)等炎性标志物指标外,基因组学、蛋白质组学、代谢组学和微生物组学已经用于诊断DF。为了进一步了解血清生物学标志物在DF诊断中的应用和研究现状,本综述将详细讨论和总结DF诊断标志物,为预防、诊断和预后评估提供相应依据。

关键词: 糖尿病足, 诊断标志物, 血清学标志物

Abstract:

Diabetic foot (DF), a primary chronic complication of diabetes mellitus, contributes to a major disability and mortality in diabetic patients. DF is diagnosed mainly depending not only on clinical manifestations, signs, and related inspection, but also on recently emerging diagnostic means: biological markers. Inflammatory biomarkers are preferably used for its superiority in DF early diagnosis. In recently years, thanks to advancements of biological technologies, biomarkers such as procalcitonin (PCT), C?reactive protein (CRP), interleukins (ILs), and tumor necrosis factor?alpha (TNF?α) have been comprehensively used in DF diagnosis. Moreover, biomarkers of genomics, proteomics, metabolomics, and metagenomics have been employed as well. In this review, we aim to comprehensively review the role of serum biomarkers in DF diagnosis and risk stratification, elaborating on the current research status in applying serum biomarkers for DF prevention, diagnosis, and prognosis assessment.

Key words: diabetic foot, diagnostic marker, serological biomarkers

中图分类号: